Eli Lilly and Company announced a collaboration with BigHat Biosciences to advance its machine-learning biologics discovery platform, TuneLab. BigHat will leverage its AI expertise and Milliner™ platform. This effort aims to enhance the development of therapeutic antibody candidates.
The partnership expands on a previous relationship between the two companies. That prior work focused on engineering next-generation antibody therapeutics.
Separately, Lilly is in advanced discussions to acquire Ventyx Biosciences. The potential acquisition is valued at over $1 billion.
This move would significantly expand Lilly’s immunology portfolio, adding promising treatments for inflammatory diseases. Following the news of these strategic initiatives, Lilly’s shares rose.